Evidence map›Paper›PMID 31774689›Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2020

A disintegrin and metalloproteinase 12 prevents heart failure by regulating cardiac hypertrophy and fibrosis.

Yuto Nakamura, Shunbun Kita, Yoshimitsu Tanaka, Shiro Fukuda, Yoshinari Obata, Tomonori Okita, Yusuke Kawachi, Yuri Tsugawa-Shimizu, Yuya Fujishima, Hitoshi Nishizawa and 5 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Yuto NakamuraDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Shunbun KitaDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.ORCID 0000-0002-8937-0053
Yoshimitsu TanakaDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Shiro FukudaDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yoshinari ObataDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Tomonori OkitaDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yusuke KawachiDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yuri Tsugawa-ShimizuDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yuya FujishimaDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.ORCID 0000-0003-0028-1757
Hitoshi NishizawaDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Shigeru MiyagawaDepartment of Cardiovascular Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yoshiki SawaDepartment of Cardiovascular Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Atsuko Sehara-FujisawaDepartment of Growth Regulation, Institute for Frontier 11 Medical Sciences, Kyoto University, Kyoto, Japan.
Norikazu MaedaDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Iichiro ShimomuraDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
The University of Osaka · JPKowa (Japan) · JPKyoto University · JPOsaka University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A disintegrin and metalloproteinase (ADAM)12 is considered to promote cardiac dysfunction based on the finding that a small-molecule ADAM12 inhibitor, KB-R7785, ameliorated cardiac function in a transverse aortic constriction (TAC) model by inhibiting the proteolytic activation of heparin-binding-EGF signaling. However, this compound has poor selectivity for ADAM12, and the role of ADAM12 in cardiac dysfunction has not yet been investigated using genetic loss-of-function mice. We revealed that ADAM12 knockout mice showed significantly more advanced cardiac hypertrophy and higher mortality rates than wild-type mice 4 wk after TAC surgery. An ADAM12 deficiency resulted in significantly more expanded cardiac fibrosis accompanied by increased collagen-related gene expression in failing hearts. The results of a genome-wide transcriptional analysis suggested a strongly enhanced focal adhesion- and fibrosis-related signaling pathway in ADAM12 knockout hearts. The loss of ADAM12 increased the abundance of the integrinβ1 subunit and transforming growth factor (TGF)-β receptor types I and III, and this was followed by the phosphorylation of focal adhesion kinase, Akt, mammalian target of rapamycin, ERK, and Smad2/3 in the heart, which resulted in cardiac dysfunction. The present results revealed that the loss of ADAM12 enhanced focal adhesion and canonical TGF-β signaling by regulating the abundance of the integrinβ1 and TGF-β receptors.

Indexed as

ADAM12 ProteinAnimalsBlood PressureCardiomegalyDisintegrinsFibrosisFocal AdhesionsHeart FailureIntegrin beta1MaleMiceMice, Inbred C57BLMice, KnockoutMyocardiumReceptors, Transforming Growth Factor betaSignal TransductionADAM12 ProteinAdam12 protein, mouseDisintegrinsIntegrin beta1Receptors, Transforming Growth Factor betaADAM12cardiac hypertrophyfibrosisfocal adhesion

Identifiers

PMID31774689
OpenAlexW2990679521

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.